The University of Chicago Header Logo

Connection

Jessica J. Kandel to Mice

This is a "connection" page, showing publications Jessica J. Kandel has written about Mice.
Connection Strength

0.534
  1. Human cancer cells express Slug-based epithelial-mesenchymal transition gene expression signature obtained in vivo. BMC Cancer. 2011 Dec 30; 11:529.
    View in: PubMed
    Score: 0.037
  2. Angiopoietin-1/Tie-2 activation contributes to vascular survival and tumor growth during VEGF blockade. Int J Oncol. 2009 Jan; 34(1):79-87.
    View in: PubMed
    Score: 0.030
  3. Effects of potent VEGF blockade on experimental Wilms tumor and its persisting vasculature. Int J Oncol. 2004 Sep; 25(3):549-53.
    View in: PubMed
    Score: 0.022
  4. Vascular remodeling marks tumors that recur during chronic suppression of angiogenesis. Mol Cancer Res. 2004 Jan; 2(1):36-42.
    View in: PubMed
    Score: 0.021
  5. Human epidermal growth factor receptor signaling contributes to tumor growth via angiogenesis in her2/neu-expressing experimental Wilms' tumor. J Pediatr Surg. 2003 Nov; 38(11):1569-73.
    View in: PubMed
    Score: 0.021
  6. Blockade of her2/neu decreases VEGF expression but does not alter HIF-1 distribution in experimental Wilms tumor. Oncol Rep. 2003 Sep-Oct; 10(5):1271-4.
    View in: PubMed
    Score: 0.021
  7. Regression of established tumors and metastases by potent vascular endothelial growth factor blockade. Proc Natl Acad Sci U S A. 2003 Jun 24; 100(13):7785-90.
    View in: PubMed
    Score: 0.021
  8. Histotripsy induces apoptosis and reduces hypoxia in a neuroblastoma xenograft model. Int J Hyperthermia. 2023; 40(1):2222941.
    View in: PubMed
    Score: 0.020
  9. p53 accumulation in favorable-histology Wilms tumor is associated with angiogenesis and clinically aggressive disease. J Pediatr Surg. 2002 Mar; 37(3):523-7.
    View in: PubMed
    Score: 0.019
  10. Resistance of a VEGF-producing tumor to anti-VEGF antibody: unimpeded growth of human rhabdoid tumor xenografts. J Pediatr Surg. 2002 Mar; 37(3):528-32.
    View in: PubMed
    Score: 0.019
  11. Novel use of an established agent: Topotecan is anti-angiogenic in experimental Wilms tumor. J Pediatr Surg. 2001 Dec; 36(12):1781-4.
    View in: PubMed
    Score: 0.018
  12. Combination antiangiogenic therapy: increased efficacy in a murine model of Wilms tumor. J Pediatr Surg. 2001 Aug; 36(8):1177-81.
    View in: PubMed
    Score: 0.018
  13. Highly specific antiangiogenic therapy is effective in suppressing growth of experimental Wilms tumors. J Pediatr Surg. 2001 Feb; 36(2):357-61.
    View in: PubMed
    Score: 0.017
  14. Perfusion-guided sonopermeation of neuroblastoma: a novel strategy for monitoring and predicting liposomal doxorubicin uptake in vivo. Theranostics. 2020; 10(18):8143-8161.
    View in: PubMed
    Score: 0.017
  15. Suppression of primary tumor growth in a mouse model of human neuroblastoma. J Pediatr Surg. 2000 Jun; 35(6):977-81.
    View in: PubMed
    Score: 0.017
  16. Anti-VEGF antibody suppresses primary tumor growth and metastasis in an experimental model of Wilms' tumor. J Pediatr Surg. 2000 Jan; 35(1):30-2; discussion 32-3.
    View in: PubMed
    Score: 0.016
  17. Pathological angiogenesis in a murine model of human Wilms' tumor. J Pediatr Surg. 1999 May; 34(5):676-9.
    View in: PubMed
    Score: 0.015
  18. Metastasis correlates with production of vascular endothelial growth factor in a murine model of human Wilms' tumor. J Pediatr Surg. 1999 May; 34(5):743-7; discussion 747-8.
    View in: PubMed
    Score: 0.015
  19. A metastasizing model of anaplastic human Wilms tumor in the nude mouse. Eur J Pediatr Surg. 1998 Oct; 8(5):295-8.
    View in: PubMed
    Score: 0.015
  20. Transcription factor activating protein 4 is synthetically lethal and a master regulator of MYCN-amplified neuroblastoma. Oncogene. 2018 10; 37(40):5451-5465.
    View in: PubMed
    Score: 0.015
  21. Notch suppresses angiogenesis and progression of hepatic metastases. Cancer Res. 2015 Apr 15; 75(8):1592-602.
    View in: PubMed
    Score: 0.012
  22. Aberrant lymphatic endothelial progenitors in lymphatic malformation development. PLoS One. 2015; 10(2):e0117352.
    View in: PubMed
    Score: 0.012
  23. Evaluating tumor angiogenesis. Methods Mol Biol. 2013; 980:341-51.
    View in: PubMed
    Score: 0.010
  24. Contrast ultrasound imaging for identification of early responder tumor models to anti-angiogenic therapy. Ultrasound Med Biol. 2012 Jun; 38(6):1019-29.
    View in: PubMed
    Score: 0.009
  25. Monitoring early tumor response to drug therapy with diffuse optical tomography. J Biomed Opt. 2012 Jan; 17(1):016014.
    View in: PubMed
    Score: 0.009
  26. Neovascularization is associated with a switch to the export of bFGF in the multistep development of fibrosarcoma. Cell. 1991 Sep 20; 66(6):1095-104.
    View in: PubMed
    Score: 0.009
  27. Polyplex-microbubble hybrids for ultrasound-guided plasmid DNA delivery to solid tumors. J Control Release. 2012 Jan 30; 157(2):224-34.
    View in: PubMed
    Score: 0.009
  28. Vascular endothelial growth factor blockade rapidly elicits alternative proangiogenic pathways in neuroblastoma. Int J Oncol. 2009 Feb; 34(2):401-7.
    View in: PubMed
    Score: 0.008
  29. A notch1 ectodomain construct inhibits endothelial notch signaling, tumor growth, and angiogenesis. Cancer Res. 2008 Jun 15; 68(12):4727-35.
    View in: PubMed
    Score: 0.007
  30. Sustained VEGF blockade results in microenvironmental sequestration of VEGF by tumors and persistent VEGF receptor-2 activation. Mol Cancer Res. 2008 Jan; 6(1):1-9.
    View in: PubMed
    Score: 0.007
  31. Inhibition of cyclooxygenase-2 disrupts tumor vascular mural cell recruitment and survival signaling. Cancer Res. 2006 Apr 15; 66(8):4378-84.
    View in: PubMed
    Score: 0.006
  32. TNP-470 promotes initial vascular sprouting in xenograft tumors. Mol Cancer Ther. 2004 Mar; 3(3):335-43.
    View in: PubMed
    Score: 0.005
  33. Thalidomide is anti-angiogenic in a xenograft model of neuroblastoma. Int J Oncol. 2003 Dec; 23(6):1651-5.
    View in: PubMed
    Score: 0.005
  34. Anti-VEGF antibody in experimental hepatoblastoma: suppression of tumor growth and altered angiogenesis. J Pediatr Surg. 2003 Mar; 38(3):308-14; discussion 308-14.
    View in: PubMed
    Score: 0.005
  35. Potent VEGF blockade causes regression of coopted vessels in a model of neuroblastoma. Proc Natl Acad Sci U S A. 2002 Aug 20; 99(17):11399-404.
    View in: PubMed
    Score: 0.005
  36. Topotecan is anti-angiogenic in experimental hepatoblastoma. J Pediatr Surg. 2002 Jun; 37(6):857-61.
    View in: PubMed
    Score: 0.005
  37. Distinct response of experimental neuroblastoma to combination antiangiogenic strategies. J Pediatr Surg. 2002 Mar; 37(3):518-22.
    View in: PubMed
    Score: 0.005
  38. All angiogenesis is not the same: Distinct patterns of response to antiangiogenic therapy in experimental neuroblastoma and Wilms tumor. J Pediatr Surg. 2001 Feb; 36(2):287-90.
    View in: PubMed
    Score: 0.004
  39. Endothelial-monocyte activating polypeptide II, a novel antitumor cytokine that suppresses primary and metastatic tumor growth and induces apoptosis in growing endothelial cells. J Exp Med. 1999 Aug 02; 190(3):341-54.
    View in: PubMed
    Score: 0.004
  40. Intrinsic mitogenic potential of canine flexor tendons. J Hand Surg Br. 1992 Jun; 17(3):275-7.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.